GlassScriptPhysician profile
Tracie Lynn White
NPI 1912928698
$3,983.05
in general payments reported to CMS, 2019-2025
31 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what 86% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $476 · 2022: $475 · 2023: $388 · 2024: $1,529 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,032.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $336.79 | 2024-2025 | Cequr Simplicity |
| Amgen INC. | $329.48 | 2021-2025 | Repatha, Tepezza, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $318.29 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $287.03 | 2021-2025 | |
| Novo Nordisk INC | $271.87 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Actelion Pharmaceuticals US, INC. | $199.37 | 2021-2025 | Opsumit, Uptravi |
| Boston Scientific Corporation | $191.97 | 2021-2025 | Watchman Flx, Watchman, Watchman Access System |
| Alnylam Pharmaceuticals INC. | $181.49 | 2021-2025 | Onpattro |
| Inspire Medical Systems, INC. | $172.46 | 2024-2025 | Inspire |
| Medtronic, INC. | $169.08 | 2023-2024 | Cobalt Dr Mri Surescan, Linq II, Micra |
| E.R. Squibb & Sons, L.L.C. | $165.85 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $153.44 | 2022-2025 | |
| Abbott Laboratories | $143.89 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Janssen Pharmaceuticals, INC | $140.01 | 2021-2024 | Xarelto |
| Daiichi Sankyo INC. | $131.77 | 2022-2025 | Injectafer |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $115.92 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.62 | 2022-2025 | Jardiance |
| Lilly USA, LLC | $99.29 | 2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $81.15 | 2021-2025 | Verquvo |
| Edwards Lifesciences Corporation | $66.43 | 2021-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Scpharmaceuticals INC. | $51.49 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $49.28 | 2021-2024 | Andexxa, Wainua |
| Bayer Healthcare Pharmaceuticals INC. | $41.60 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $37.74 | 2021 | |
| Genzyme Corporation | $30.69 | 2024 | |
| Bridgebio Pharma, INC. | $22.99 | 2025 | Attruby |
| Baxter Healthcare | $19.33 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Amarin Pharma, INC. | $15.64 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $15.48 | 2023 | Inpefa |
| Esperion Therapeutics, INC. | $15.22 | 2025 | Nexletol |
| Livanova USA, INC. | $14.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracie White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.